What is a stock summary page? Click here for an overview.
Business Description
HCW Biologics Inc
NAICS : 541714
SIC : 2834
ISIN : US40423R1059
Description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.34 | |||||
| Equity-to-Asset | -0.22 | |||||
| Debt-to-Equity | -2.02 | |||||
| Debt-to-EBITDA | -0.5 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -8.47 | |||||
| Beneish M-Score | -4.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -2.9 | |||||
| 3-Year EPS without NRI Growth Rate | 19.5 | |||||
| 3-Year FCF Growth Rate | 14 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -15.76 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.94 | |||||
| 9-Day RSI | 22.42 | |||||
| 14-Day RSI | 32.4 | |||||
| 3-1 Month Momentum % | -15.96 | |||||
| 6-1 Month Momentum % | -21.12 | |||||
| 12-1 Month Momentum % | -77.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.19 | |||||
| Quick Ratio | 0.19 | |||||
| Cash Ratio | 0.16 | |||||
| Days Sales Outstanding | 123.11 | |||||
| Days Payable | 3565.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.6 | |||||
| Shareholder Yield % | -93.73 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 37.36 | |||||
| Operating Margin % | -680.25 | |||||
| Net Margin % | -1169.58 | |||||
| FCF Margin % | -564.39 | |||||
| ROA % | -105.3 | |||||
| ROIC % | -65.76 | |||||
| 3-Year ROIIC % | 1.99 | |||||
| ROC (Joel Greenblatt) % | -129.33 | |||||
| ROCE % | -385.05 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.6 | |||||
| EV-to-EBIT | -0.75 | |||||
| EV-to-Forward-EBIT | -2.74 | |||||
| EV-to-EBITDA | -0.78 | |||||
| EV-to-Revenue | 8.44 | |||||
| EV-to-Forward-Revenue | 23.34 | |||||
| EV-to-FCF | -1.5 | |||||
| Price-to-GF-Value | 0.25 | |||||
| Earnings Yield (Greenblatt) % | -133.33 | |||||
| FCF Yield % | -135.07 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers